Health
Why Regeneron Is Halting Coronavirus Antibody Cocktail Study Enrollment In Patients With Severe Cases – Benzinga
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) faced a setback Friday in a trial evaluating its antibody cocktail REGN-COV2 in hospitalized COVID-19 …
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) faced a setback Friday in a trial evaluating its antibody cocktail REGN-COV2 in hospitalized COVID-19 patients.
What Happened: An independent data monitoring committee recommended that further enrollment of patients requiring high-flow oxygen or mechanical ventilation be placed on hold, citing a potential safety signal and an unfavorable risk-benefit profile at this time, Regeneron said Friday.
The committee recommended continuing the enrollment of hospitalized…
-
Noosa News24 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
Business21 hours agoThese ASX 200 shares could rise 50% to 60%
-
General21 hours agoAustralia’s Myanmar community mourns earthquake losses
-
General23 hours agoPort’s lease a ‘mistake’ as major parties flag takeover